8% Surge in Molecular Glue New Drug Stocks... Will Clinical Momentum Ignite Again?

U.S. biotech stock Monte Rosa Therapeutics Inc. (NASDAQ: GLUE) closed at $24.20 on the Nasdaq, up 8.57% for the day. Trading volume was roughly 1.55 million shares, and market capitalization rose by about $192 million to approximately $2.044 billion—equivalent to about KRW 2.8 trillion and KRW 270 billion, respectively.

In its March 17 earnings release, the company said it plans to begin Phase 2 trials sequentially from 2026 for three clinical programs—MRT-8102, MRT-6160, and MRT-2359—and that its cash reserves are sufficient to fund operations through 2029 (see ir.monterosatx.com).

Inflammation candidate MRT-8102 showed significant reductions in high-sensitivity C-reactive protein (hs-CRP) among subjects, including a high-risk cardiovascular cohort, in early clinical data. Additional results from the expanded GFORCE-1 study are expected in the second half of 2026, making it a potential catalyst for the stock (see marketscreener.com).

Founded in 2018, Monte Rosa Therapeutics is a clinical-stage biotech company developing tumor, autoimmune, and inflammatory disease treatments using its proprietary “molecular glue” technology to selectively degrade proteins in the body (see stockanalysis.com).

Since its 2021 Nasdaq listing, the company has not yet commercialized any products and is viewed as a high-risk growth stock with significant price swings driven by partnerships and clinical data. Its alliances with Novartis and Roche are valued at up to $5.7 billion (see hbmpartners.com).